SEC Charges Bristol-Myers Squibb Executive with Insider Trading in Stock Options of Potential Acquisition Targets

The SEC charged an executive at Bristol-Myers Squibb with insider trading on confidential information about companies being targeted for potential acquisitions. The SEC alleges that the executive profited by misusing nonpublic information he obtained while helping his employer evaluate whether to acquire three other pharmaceutical companies.

Cross-Reference(s): Securities Act Section 17(a); Exchange Act Sections 10(b) and 14(e), Rules 10b-5 and 14e-3.

View in full here (links externally to SEC website).Additional Materials: SEC Complaint; More SEC Insider Trading Cases.